Takeda Pharmaceuticals North America, Inc. (TPNA) announced that the company will revise warnings related to congestive heart failure (CHF) in the prescribing label of its type 2 diabetes medication ACTOS(R) (pioglitazone HCl).
On June 5, 2007, the New England Journal of Medicine published results of an interim analysis of the cardiovascular safety trial of rosiglitazone (brand name, Avandia).
Abbott announced that it received European CE Mark (Conformit? Europ?ene) approval for the FreeStyle Navigator? Continuous Glucose Monitoring System for people with diabetes.
An easily identifiable dermatologic condition, acanthosis nigricans, is associated with having multiple risk factors for type 2 diabetes, in patients aged 7 to 39 years, finds this study of 1,113 patients.
Nutrition 21, Inc. (NASDAQ: NXXI) announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome?, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).
Januvia (scientific name sitagliptin), a new drug designed to improve blood sugar control in patients with type 2 diabetes, should not be used because the drug?s long-term safety is still unknown, Public Citizen writes in a new June posting on its WorstPills.org Web site.
University of Florida researchers have begun a clinical study of oral insulin to prevent or delay type 1 diabetes in people at risk for the disease.
Researchers have shown that key chemicals that carry cholesterol and fats in the blood accumulate in people with type 2 diabetes, which may help improve treatment of this disease.
“Dramatic” losses of a key biochemical substance in heart muscle tissue occur in the very earliest stages of diabetes induced in laboratory mice, scientists in Missouri are reporting in the May 29 issue of ACS’ Biochemistry, a weekly journal.
US Governor Edward G. Rendell signed two executive orders to improve how Pennsylvanians with chronic disease receive health care in the future. Both initiatives are part of the Governor?s Prescription for Pennsylvania health care reform plan.